Honokiol alleviates sepsis-associated cardiac dysfunction via attenuating inflammation, apoptosis and oxidative stress

J Pharm Pharmacol. 2023 Mar 12;75(3):397-406. doi: 10.1093/jpp/rgac102.

Abstract

Objective: Honokiol, a natural active compound extracted from Chinese herbal medicine, can ameliorate acute lung and kidney injury of sepsis. This study was to explore the effects of honokiol on sepsis-associated cardiac dysfunction and the underlying mechanism.

Methods: Septic mice were induced by cecal ligation and puncture (CLP) or lipopolysaccharide (LPS), and septic HL-1 or AC16 cells were induced by LPS.

Results: Honokiol improved the survival and alleviated cardiac dysfunction in mice with CLP-induced sepsis. Honokiol inhibited the increased interleukin (IL) 1-β, IL-6 and tumour necrosis factor (TNF)-α in the serum and heart of CLP- and LSP-induced septic mice. Honokiol treatment reversed the increased levels of IL1-β, IL-6 and TNF-α in LPS-induced HL-1 cells. Honokiol treatment also decreased the elevated levels of IL1-β, IL-6 and TNF-α in LPS-induced AC16 cells. The increased cardiac apoptosis in CLP- and LPS-induced septic mice was alleviated by honokiol. The enhancement of oxidative stress in the heart of CLP- and LPS-induced septic mice was suppressed after honokiol administration.

Conclusion: These results showed that honokiol could ameliorate sepsis-associated cardiac dysfunction via attenuating inflammation, apoptosis, and oxidative stress. Honokiol is a prospective drug for sepsis-associated heart damage in the future.

Keywords: Honokiol; apoptosis; cardiac dysfunction; inflammation; oxidative stress; sepsis.

MeSH terms

  • Animals
  • Apoptosis
  • Heart Diseases*
  • Inflammation / drug therapy
  • Interleukin-6
  • Lipopolysaccharides / pharmacology
  • Mice
  • Oxidative Stress
  • Sepsis* / drug therapy
  • Tumor Necrosis Factor-alpha

Substances

  • honokiol
  • Tumor Necrosis Factor-alpha
  • Interleukin-6
  • Lipopolysaccharides